Table 1: Results from clinical trials of single chemotherapy or combined with an antiangiogenic agent.

ClinicalTrials.gov identifierAntiangiogenic agentsCytostatic agentsProgression-free survival

NCT00219557AxitinibGemcitabine
Gemcitabine
116 days (109 to 160)
113 days (68 to 205)
NCT00532155AfliberceptDocetaxel
Docetaxel
5.19 months (4.37 to 5.55)
4.11 months (3.52 to 4.34)
NCT00434252BevacizumabCarboplatin, Paclitaxel
Carboplatin, Paclitaxel
5.6 months (4.21 to 6.80)
4.2 months (2.83 to 5.36)
NCT00687297Vandetanib
4 cycles and maintenance treatment
Docetaxel, Carboplatin4.5 months (3.3 to 5.8)
Vandetanib
4 cycles only, no maintenance treatment
Docetaxel, Carboplatin4.2 months (2.8 to 4.9)

NCT00130728Erlotinib, Bevacizumab3.4 months (2.79 to 4.27)
Bevacizumab1.7 months (1.48 to 2.53)